DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric cancer. Enhertu is a HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo. According to AstraZeneca, the antibody drug conjugate delivered the desired tumor response in patients suffering […]